Salvat

Executive Summary

Salvat is a privately-held, family-owned Spanish pharmaceutical company established in 1955 and headquartered in Barcelona. The company is fully integrated, focusing on the development and commercialization of small molecule therapeutics for Otolaryngology (ENT) and Ophthalmology. Salvat's strategy emphasizes organic growth, technological innovation, and a robust international presence. With approved products in its portfolio, the company leverages its decades of experience to address unmet medical needs in niche therapeutic areas. Its private status allows for long-term strategic investments without quarterly earnings pressure, positioning it as a stable player in the specialty pharmaceutical landscape. The company's commitment to R&D and its established commercial infrastructure in Europe and select international markets underpin its potential for sustained growth.

Upcoming Catalysts (preview)

• Q3 2026Potential launch of a new ENT formulation in Europe70% success
• TBDRegulatory filing for an ophthalmology product in key markets50% success
• TBDPartnership or licensing deal for international expansion40% success